Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis

BACKGROUND: Inhibition of programmed death-ligand 1 (PD-L1) with atezolizumab can induce durable clinical benefit (DCB) in patients with metastatic urothelial cancers, including complete remissions in patients with chemotherapy refractory disease. Although mutation load and PD-L1 immune cell (IC) st...

Descripción completa

Detalles Bibliográficos
Autores principales: Snyder, Alexandra, Nathanson, Tavi, Funt, Samuel A., Ahuja, Arun, Buros Novik, Jacqueline, Hellmann, Matthew D., Chang, Eliza, Aksoy, Bulent Arman, Al-Ahmadie, Hikmat, Yusko, Erik, Vignali, Marissa, Benzeno, Sharon, Boyd, Mariel, Moran, Meredith, Iyer, Gopa, Robins, Harlan S., Mardis, Elaine R., Merghoub, Taha, Hammerbacher, Jeff, Rosenberg, Jonathan E., Bajorin, Dean F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5446110/
https://www.ncbi.nlm.nih.gov/pubmed/28552987
http://dx.doi.org/10.1371/journal.pmed.1002309

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5446110/
https://www.ncbi.nlm.nih.gov/pubmed/28552987
http://dx.doi.org/10.1371/journal.pmed.1002309

Ejemplares similares